Search research articles
Contact Us
Filters
Showing results (171-180 of 188) with videos related to
Page
of 19
Sort By:
Future Oncology (London, England)
|
May 15, 2025
Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer
Luis G Paz-Ares, Oscar Juan-Vidal, Giannis S Mountzios, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2024
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study
Luis G Paz-Ares, Oscar Juan-Vidal, Giannis S Mountzios, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 13, 2024
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial
Martin Reck, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 6, 2024
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis
Solange Peters, Luis G Paz-Ares, Martin Reck, et al.
Cancer Research Communications
|
April 26, 2024
First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study
Duncan A Wheatley, Rossana Berardi, Miguel A Climent Duran, et al.
ESMO Open
|
May 30, 2025
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA
D P Carbone, T-E Ciuleanu, M Cobo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 22, 2022
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis
H Borghaei, T-E Ciuleanu, J-S Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 12, 2022
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227
Julie R Brahmer, Jong-Seok Lee, Tudor-Eliade Ciuleanu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 6, 2017
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
Dong-Wan Kim, Marcello Tiseo, Myung-Ju Ahn, et al.
JTO Clinical and Research Reports
|
September 6, 2022
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory <i>ALK</i>+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
Scott N Gettinger, Rudolf M Huber, Dong-Wan Kim, et al.
Page
of 19
Search research articles
Search
Showing results (171-180 of 188) with videos related to
Sort By:
Page
of 19
Future Oncology (London, England)
|
May 15, 2025
Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer
Luis G Paz-Ares, Oscar Juan-Vidal, Giannis S Mountzios, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2024
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study
Luis G Paz-Ares, Oscar Juan-Vidal, Giannis S Mountzios, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 13, 2024
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial
Martin Reck, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 6, 2024
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis
Solange Peters, Luis G Paz-Ares, Martin Reck, et al.
Cancer Research Communications
|
April 26, 2024
First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study
Duncan A Wheatley, Rossana Berardi, Miguel A Climent Duran, et al.
ESMO Open
|
May 30, 2025
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA
D P Carbone, T-E Ciuleanu, M Cobo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 22, 2022
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis
H Borghaei, T-E Ciuleanu, J-S Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 12, 2022
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227
Julie R Brahmer, Jong-Seok Lee, Tudor-Eliade Ciuleanu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 6, 2017
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
Dong-Wan Kim, Marcello Tiseo, Myung-Ju Ahn, et al.
JTO Clinical and Research Reports
|
September 6, 2022
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory <i>ALK</i>+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
Scott N Gettinger, Rudolf M Huber, Dong-Wan Kim, et al.
Page
of 19